Abiopharma

Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel®

MOONLAKE IMMUNOTHERAPEUTICS SECURITIES FRAUD NOTICE: Berger Montague Informs MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors of Securities Fraud Lawsuit

Creative Medical Technology Holdings Issues Letter to Shareholders

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Dominari Holdings Inc. (NASDAQ: DOMH)

HCA Announces Proposed Public Offering of Senior Notes

Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights

Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer